（来源：木鱼ETF）先说一下隔夜的突发利空消息。“根据《纽约时报》报道，特朗普政府正在起草一项行政命令，计划对中国药品（尤其是实验性药物）实施严格限制。这一政策旨在遏制中国生物科技行业的快速发展，但可能对美国制药业供应链和患者获取创新疗法造成深远影响。”消息内容不详细，但懂王还在“考虑”，但有可能通过。这个命令，字面上对于BD、license-out这种创新药授权影响不大，但是很可能让投资者联想到...
Source Link（来源：木鱼ETF）先说一下隔夜的突发利空消息。“根据《纽约时报》报道，特朗普政府正在起草一项行政命令，计划对中国药品（尤其是实验性药物）实施严格限制。这一政策旨在遏制中国生物科技行业的快速发展，但可能对美国制药业供应链和患者获取创新疗法造成深远影响。”消息内容不详细，但懂王还在“考虑”，但有可能通过。这个命令，字面上对于BD、license-out这种创新药授权影响不大，但是很可能让投资者联想到...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.